AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy
Phase 3
Completed
- Conditions
- Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy
- Interventions
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2015-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 279
- Registration Number
- NCT01961349
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 117
- Registration Number
- NCT01960374
- Locations
- 🇬🇧
Research Site, London, United Kingdom
To Assess Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses.
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 157
- Registration Number
- NCT01958645
- Locations
- 🇬🇧
Research Site, London, United Kingdom
MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients
Phase 2
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: MEDI7183 high doseDrug: MEDI7183 low doseDrug: Matching PlaceboDrug: MEDI7183 medium dose
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT01959165
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT01957579
- Locations
- 🇯🇵
Research Site, Nagoya-shi, Japan
AZD6738 First Time in Patient Multiple Ascending Dose Study
Phase 1
Completed
- Conditions
- 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),Prolymphocytic Leukaemia (PLL)B Cell Lymphomas
- Interventions
- Drug: Administration of AZD6738
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2014-06-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2
- Registration Number
- NCT01955668
- Locations
- 🇺🇸
Research Site, La Jolla, California, United States
A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.
Completed
- Conditions
- Locally Advanced or Metastatic EGFR Mutated NSCLC.
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT01955681
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Completed
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4992
- Registration Number
- NCT01952392
- Locations
- 🇫🇷
Research Site, Paris, France
To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT01951599
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
Phase 1
Terminated
- Conditions
- Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT01949870
- Locations
- 🇯🇵
AZD6244 PhI Japanese Gem/, Chuo Ku, Tokyo, Japan